


PHARMACEUTICAL 2020

NeuBase Therapeutics Inc. Rank 347 of 362





PHARMACEUTICAL 2020

NeuBase Therapeutics Inc. Rank 347 of 362

The relative strengths and weaknesses of NeuBase Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuBase Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 179% points. The greatest weakness of NeuBase Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 793% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,309%, being 1,006% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	11,029
Cost of Goods Sold	0
Intangible Assets	146
Liabilities, Current	2,502
Liabilities, Non-Current	0
Other Assets	925
Other Compr. Net Income	0
Other Expenses	13,589
Other Liabilities	0
Other Net Income	0
Property and Equipment	431
Research and Development	4,273
Revenues	0
Selling, General and Administrative Expense	9,096

Output Variable	Value in 1000 USD
Assets	12,531
Liabilities	2,502
Expenses	26,958
Stockholders Equity	10,029
Net Income	-26,958
Comprehensive Net Income	-26,958
Economic Capital Ratio	-1,309%